Complain about a product or service

New Cancer Drug May Be On the Way

New method is stronger yet less harmful than most chemo

January 22, 2008

Cancer • Mayo Researchers Report Cancer Breakthrough • Late-State Cancer Risk Higher In City Than In Country • Complementary Methods Used to Deal With Cancer • Researchers Report Cancer Breakthrough • Great Lakes Region A Potential Graveyard • Oral Sex Can Cause Cancer in Men • New Cancer Drug May Be On the Way • Thinking Positive Does Little To Help Cancer Survival • FDA Issues Warning about Fentora • Cancer Painkiller Can Be Fatal, Manufacturer Warns • A Gene That “Turns Off” Cancer? • Key to Reducing Cancer Risk Not a Mystery • Researchers Study NSAIDs and Cancer • Vitamin D May Protect Against Some Cancer • Report Tracks Decline In Cancer Deaths • Popular Cancer Drug Called "Toxic" To Heart • Colorectal Cancer Risk Higher for Smokers, Drinkers and Men • Health Groups Dispute Low Fat Study Findings • Research: Veggies May Protect Against Cancer • Total Cancer Deaths Down This Year • Circumcision May Protect Against Cervical Cancer • Study: Low-Fat Diet Does Little to Reduce Breast Cancer Risk • Study Finds Teflon Chemical In Newborns' Umbilical Cords • Study: Omega-3 Consumption Not Linked to Reduced Risk of Cancer • Canine Cancer Detectors • Is Lung Cancer Becoming a Woman's Disease? • Prostate Cancer Genes Identified

Johns Hopkins researchers say they have discovered a previously unsuspected way to kill cancer cells that could lead to stronger yet less harmful cancer drugs. Their findings appear in the Early Edition of the Proceedings of the National Academy of Sciences.

"A major hang-up in cancer chemotherapy is the toxicity caused by DNA disruption of cell division throughout the body. Our research suggests that drugs like cisplatin and novobiocin kill cells as much from this newly discovered mechanism as any other mechanism of cell death," said Solomon H. Snyder, M.D., a professor of neuroscience at Hopkins.

"Targeting this new mechanism in drug design might make for therapies with fewer side effects."

Snyder and colleagues previously had discovered that cell stressors, including anticancer drugs, rapidly activate a protein called IP6K2, which promotes cell death. The team searched for proteins that bind to and potentially control IP6K2 and found a heat shock protein, called HSP90.

"This was really interesting because HSP90 is a survival protein," says Snyder. "On the one hand we have IP6K2, which is pro-death, and on the other we have the pro-life HSP90, so we thought maybe they might be duking it out in a cell."

When the team looked closer at the interactions between HSP90 and IP6K2, they found that when the two are bound to each other, IP6K2 stops working. When the researchers altered IP6K2 so that it couldn't bind HSP90, they were able to restore IP6K2 function. And presumably, according to Snyder, the cell would die.

The team then asked whether the anticancer drugs cisplatin and novobiocin, which cause cell death, somehow interfered with HSP90-IP6K2 interactions. They found that at normal, therapeutic doses, both drugs did block the two proteins from binding, enabling IP6K2 to function uninhibited.

According to Snyder, HSP90 normally binds to IP6K2 and prevents cell death. But the drugs cisplatin and novobiocin can bind to HSP90 and cause it to let go of IP6K2, freeing IP6K2 to promote cell death.

"Our findings could be applied to design new anticancer drugs that specifically block this HSP90-IP6K2 interaction. These drugs may be more selective and therefore have fewer side effects than classical chemotherapeutic agents, which can cause all sorts of DNA damage," says Snyder.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.